Why the study?
There are limited means to effectively reduce or reverse cardiac fibrosis, and identifying methods to curb excess extracellular matrix deposition requires a better understanding of cardiac fibroblasts.
Key points are not available for this paper at this time.
Design
Review
Identifies fibroblast subsets for potential targeted antifibrotic therapies; leaves open their functional validation in human disease.
Cardiac fibrosis is a pathological condition that occurs after injury and during aging. Currently, there are limited means to effectively reduce or reverse fibrosis. Key to identifying methods for curbing excess deposition of extracellular matrix is a better understanding of the cardiac fibroblast, the cell responsible for collagen production. In recent years, the diversity and functions of these enigmatic cells have been gradually revealed. In this review, I outline current approaches for identifying and classifying cardiac fibroblasts. An emphasis is placed on new insights into the heterogeneity of these cells as determined by lineage tracing and single-cell sequencing in development, adult, and disease states. These recent advances in our understanding of the fibroblast provide a platform for future development of novel therapeutics to combat cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Michelle D. Tallquist (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: